News
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
BioNxt Solutions Inc. provides update on semaglutide ODF program and platform strategy. Focus on GLP-1 receptor agonists and peptide-based therapeutics. Potential market growth and commercial outlook discussed -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
BioNxt Solutions Inc. announces major advancement in commercialization strategy with global patent portfolio expansion for sublingual drug delivery platform. Strong intellectual property and transitioning to commercialization phase -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
BioNxt Solutions Inc. signs LOI for commercialization of sublingual cladribine ODF in Eurasian Patent Organization member states, strengthening global IP position and pursuing licensing opportunities -
-
